NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis.
NIPA
NPM-ALK
anaplastic large cell lymphoma
lymphomagenesis
transplantation mouse model
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
02
2022
accepted:
07
04
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
2
6
2022
Statut:
epublish
Résumé
The NPM-ALK fusion kinase is expressed in 60% of systemic anaplastic large-cell lymphomas (ALCL). A Nuclear Interaction Partner of ALK (NIPA) was identified as a binding partner of NPM-ALK. To identify the precise role of NIPA for NPM-ALK-driven lymphomagenesis, we investigated various NPM-ALK
Identifiants
pubmed: 35646639
doi: 10.3389/fonc.2022.875117
pmc: PMC9137267
doi:
Types de publication
Journal Article
Langues
eng
Pagination
875117Informations de copyright
Copyright © 2022 Kreutmair, Lippert, Klingeberg, Albers-Leischner, Yacob, Shlyakhto, Mueller, Mueller-Rudorf, Yu, Gorantla, Miething, Duyster and Illert.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Br J Haematol. 2001 May;113(2):275-95
pubmed: 11380391
Development. 2012 Jul;139(14):2523-34
pubmed: 22696294
Blood Cancer J. 2012 Aug 10;2:e82
pubmed: 22885405
N Engl J Med. 2010 Nov 4;363(19):1812-21
pubmed: 21047225
Nat Rev Cancer. 2014 Apr;14(4):233-47
pubmed: 24658274
Leukemia. 2015 Apr;29(4):858-68
pubmed: 25249015
Blood. 1997 Oct 15;90(8):2901-10
pubmed: 9376569
Nat Med. 2005 Jun;11(6):623-9
pubmed: 15895073
Blood. 2004 Nov 15;104(10):3358-60
pubmed: 15297316
Crit Rev Oncol Hematol. 2017 Jan;109:42-50
pubmed: 28010897
Nat Med. 2014 Dec;20(12):1401-9
pubmed: 25419709
PLoS One. 2011;6(12):e28998
pubmed: 22205987
Blood. 2000 Dec 15;96(13):4319-27
pubmed: 11110708
Blood. 2017 Feb 16;129(7):823-831
pubmed: 27879258
Nature. 2011 Jan 20;469(7330):314-22
pubmed: 21248838
Oncogene. 2003 Jul 24;22(30):4642-7
pubmed: 12879008
J Biol Chem. 2012 Nov 2;287(45):37997-8005
pubmed: 22955283
Leukemia. 2020 Dec;34(12):3242-3255
pubmed: 32203142
Crit Rev Oncol Hematol. 2012 Aug;83(2):293-302
pubmed: 22440390
J Vis Exp. 2014 Oct 27;(92):e51998
pubmed: 25408172
Science. 1995 Jan 20;267(5196):316-7
pubmed: 7824924
Front Biosci (Schol Ed). 2015 Jun 01;7(2):226-35
pubmed: 25961698
Blood. 2003 Mar 1;101(5):1919-27
pubmed: 12424201
Oncogene. 2015 Apr 2;34(14):1843-52
pubmed: 24814516
Blood. 1999 Apr 15;93(8):2697-706
pubmed: 10194450
Leukemia. 2018 Mar;32(3):820-827
pubmed: 28819285
Oncogene. 2007 Feb 8;26(6):813-21
pubmed: 16909118
Cell Cycle. 2005 Nov;4(11):1515-7
pubmed: 16258267
J Clin Oncol. 2012 Jun 20;30(18):2190-6
pubmed: 22614995
Hematology Am Soc Hematol Educ Program. 2008;:280-8
pubmed: 19074097
Cancer J. 2012 Sep-Oct;18(5):450-6
pubmed: 23006951
Blood. 2019 Jul 25;134(4):383-388
pubmed: 31186273
Nat Rev Cancer. 2008 Jan;8(1):11-23
pubmed: 18097461
J Clin Invest. 2020 Jun 1;130(6):2827-2844
pubmed: 32338640
J Immunol. 2013 Dec 15;191(12):6200-7
pubmed: 24218456
Nat Rev Cancer. 2013 Oct;13(10):685-700
pubmed: 24060861
Lancet. 2019 Jan 19;393(10168):229-240
pubmed: 30522922
Cancers (Basel). 2019 Jul 30;11(8):
pubmed: 31366041
Br J Haematol. 2016 May;173(4):560-72
pubmed: 26913827
J Biol Chem. 2003 Aug 8;278(32):30028-36
pubmed: 12748172
Blood. 1985 Oct;66(4):848-58
pubmed: 3876124
Mol Cancer. 2017 Jan 30;16(1):2
pubmed: 28137304
J Biol Chem. 2007 Jun 1;282(22):15965-72
pubmed: 17389604
Nat Rev Mol Cell Biol. 2013 Jun;14(6):369-81
pubmed: 23657496
Oncogene. 2020 Feb;39(9):1904-1913
pubmed: 31754210
Int J Mol Sci. 2019 Aug 20;20(16):
pubmed: 31434245